Pfizer Inc. (NYSE:PFE) Stock Position Trimmed by DT Investment Partners LLC

DT Investment Partners LLC decreased its stake in shares of Pfizer Inc. (NYSE:PFE) by 6.9% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 52,285 shares of the biopharmaceutical company’s stock after selling 3,890 shares during the period. DT Investment Partners LLC’s holdings in Pfizer were worth $1,387,000 as of its most recent SEC filing.

Other large investors have also recently bought and sold shares of the company. Retirement Wealth Solutions LLC acquired a new position in Pfizer during the 4th quarter valued at about $26,000. Gladius Capital Management LP increased its stake in Pfizer by 102.8% during the 3rd quarter. Gladius Capital Management LP now owns 1,043 shares of the biopharmaceutical company’s stock valued at $30,000 after buying an additional 38,015 shares during the period. Teachers Insurance & Annuity Association of America acquired a new position in Pfizer during the 3rd quarter valued at about $35,000. Joseph Group Capital Management increased its stake in Pfizer by 168.3% during the 3rd quarter. Joseph Group Capital Management now owns 1,229 shares of the biopharmaceutical company’s stock valued at $36,000 after buying an additional 771 shares during the period. Finally, Sugar Maple Asset Management LLC acquired a new position in Pfizer during the 4th quarter valued at about $43,000. Institutional investors and hedge funds own 68.36% of the company’s stock.

Pfizer Stock Performance

Pfizer stock opened at $25.64 on Friday. The firm’s 50 day simple moving average is $26.28 and its 200-day simple moving average is $27.63. The company has a market cap of $145.28 billion, a P/E ratio of 18.18, a price-to-earnings-growth ratio of 0.64 and a beta of 0.64. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73. Pfizer Inc. has a fifty-two week low of $24.48 and a fifty-two week high of $31.54.

Pfizer (NYSE:PFE) last released its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share for the quarter, topping the consensus estimate of $0.48 by $0.15. The business had revenue of $17.76 billion for the quarter, compared to the consensus estimate of $17.26 billion. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The firm’s quarterly revenue was up 24.7% compared to the same quarter last year. During the same period last year, the firm posted $0.10 earnings per share. As a group, equities research analysts predict that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, March 7th. Investors of record on Friday, January 24th will be issued a dividend of $0.43 per share. This is a boost from Pfizer’s previous quarterly dividend of $0.42. This represents a $1.72 annualized dividend and a dividend yield of 6.71%. The ex-dividend date is Friday, January 24th. Pfizer’s dividend payout ratio (DPR) is currently 121.99%.

Analyst Upgrades and Downgrades

Several equities analysts have commented on the stock. Evercore ISI raised shares of Pfizer to a “strong-buy” rating in a research note on Wednesday, October 30th. Guggenheim reaffirmed a “buy” rating and issued a $33.00 price objective on shares of Pfizer in a research note on Monday. Citigroup lowered their price objective on shares of Pfizer from $30.00 to $29.00 and set a “neutral” rating on the stock in a research note on Tuesday, January 28th. Wolfe Research initiated coverage on shares of Pfizer in a research note on Friday, November 15th. They issued an “underperform” rating and a $25.00 price objective on the stock. Finally, Truist Financial lowered their price objective on shares of Pfizer from $36.00 to $32.00 and set a “buy” rating on the stock in a research note on Wednesday, December 18th. One investment analyst has rated the stock with a sell rating, eight have given a hold rating, six have assigned a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $31.92.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.